DBD Search
Irit Ben-Chelouche
Director of Business Development, Harvard Medical School
Displaying: 21 - 30 of 80 Results
Invention
First in class substrate-selective Insulin Degrading Enzyme (IDE) inhibitors for treating Diabetes
First in class substrate-selective Insulin Degrading Enzyme (IDE) inhibitors for treating Diabetes. Professor David Liu and a multidisciplinary research team have recently discovered and optimized of a series of small molecules (<550 Da, IC50 = 1…
Investigators
- David R. Liu
- Juan Pablo Maianti
Invention
Therapeutic strategies for autism spectrum disorder sensory (tactile) hypersensitivity, anxiety and social interaction deficits
This is a novel strategy to treat tactile hypersensitivity, anxiety, and social interaction deficits by targeting the peripheral nervous system without drugging the brain.Autism spectrum disorders (ASDs), including Rett Syndrome, as well as Fragile…
Investigators
- David Ginty
- Lauren Orefice
Invention
A novel and effective technology for target-based screening
Target-based screening allows for rapid identification of ligands for an increasing number of macromolecular targets and is commonly used in drug discovery.The present invention uses interaction-dependent PCR (IDPCR) to selectively identify…
Investigators
- David R. Liu
- Christoph E. Dumelin
- David J. Gorin
- Lynn McGregor
Invention
Targeting spiral ganglion neurons for treatment of hearing loss
Hearing loss makes interactions with the world challenging for over 30 million people in the United States. While cochlear implants and hearing aid devices can ameliorate hearing loss, they often fail to restore the function of spiral ganglion…
Investigators
- Lisa Goodrich
Invention
Genomic Analysis Tool Box
Cancer genomes frequently harbor high mutation rates, complex structural variations, and are characterized by genome instability. Detailed understanding of these characteristics of the cancer genome is necessary for pinpointing the cause of tumor…
Investigators
- Peter Park
Invention
A system for in vivo generation of protective CD8+ T lymphocytes and other cells of hematopoietic origin
Differentiated CD8+ effector T cells mediate long-term immunity and protection against infectious diseases and cancer. Naive T cells are refractory to transduction with viral vectors without extensive ex vivo manipulations. A team of researchers at…
Investigators
- Arlene H. Sharpe
- Nicholas Haining
Invention
Immunology and Computational Biology Partnership
Professors Diane Mathis and Christophe Benoist at Harvard Medical School, together with other world-renowned immunologists and computational biologists from multiple research institutions, have created the Immunological Genome Project – Immgen…
Investigators
- Diane J. Mathis
- Christophe O. Benoist
Invention
Bisphosphonates as novel adjuvants to enhance the adaptive immune response, validated with common types of vaccine antigens and commercial vaccines
Despite decades of adjuvant research, only a handful of adjuvants have been approved in seven major global markets and only two (Alum and GSK’s AS04) are licensed in the US. The availability of additional adjuvants has been minimized due to…
Investigators
- Ulrich H. von Andrian
- Matteo Iannacone
- Elena Tonti
- Elliott Ashley Moseman
Invention
Small-molecule-triggered intein splicing as a universal switch for protein activation
Researchers in the laboratory of Professor David Liu have used directed evolution techniques to evolve an intein-based molecular switch that transduces binding of a small molecule into the activation of an arbitrary protein of interest. To create…
Investigators
- David R. Liu
- Allen R. Buskirk
- Sun H. Peck
Invention
Fzd2 - novel anti-cancer therapeutic target
The role of β-catenin accumulation in the development of tumorigenicity has been well documented to date, with various mutations in β-catenin, APC, and axin genes typically to blame. Although β-catenin accumulation plays a role in hepatocellular…
Investigators
- Gavin MacBeath
- Taran S. Gujral